- Zacks Small Cap Research•2 days ago
Operational Update: Feasibility Study Done, Safety Appears Non-Issue. In mid-March AEMD announced the completion of their U.S. feasibility study. While expected to enroll 10 subjects, final enrollment was 8 patients with ESRD or HCV – which the company deemed sufficient given no evidence of treatment-related adverse events (i.e.
- PR Newswire•6 days ago
SAN DIEGO, April 24, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), today released the following shareholder update authored by its Chairman and CEO, Jim Joyce. On December 13, 2016, the EAP program was further enhanced when the 21st Century Cures Act was signed into law. The legislation established a designation for "breakthrough" technologies that address diseases or conditions for which no cleared or approved alternatives exist and whose availability is in the best interest of patients.
- PR Newswire•26 days ago
SAN DIEGO, April 4, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, disclosed today that an interview conducted with Company CEO Jim Joyce on the weekly Tech Nation radio program is available to be accessed online at https://www.podomatic.com/podcasts/technation/episodes/2017-03-31T04_14_59-07_00. The 27 minute interview begins at minute six of the program and ends at minute 33. Tech Nation is a weekly public radio program, hosted by Dr. Moira Gunn. Founded in 1993, the program features conversations with noted technology and science leaders, and a weekly science and technology-related commentary. In the U.S., Tech Nation, and its regular segment BioTech Nation, can be heard multiple times each week on the NPR Channel of SiriusXM Satellite Radio and SiriusXM Internet Radio.
AEMD : Summary for Aethlon Medical, Inc. - Yahoo Finance
Aethlon Medical, Inc. (AEMD)
Other OTC - Other OTC Real Time Price. Currency in USD
Add to watchlist
|Bid||2.00 x 1500|
|Ask||6.57 x 5000|
|Day's Range||2.19 - 2.39|
|52 Week Range||2.05 - 9.09|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.59|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|